Chr. Hansen Holding A/S

Chr. Hansen is a biosciences group based in Denmark. Co. develops and supplies natural ingredient solutions for the food, pharmaceutical, nutritional, and agricultural industries worldwide. Co. operates in three divisions: Cultures and Enzymes (develops, produces, and sells cultures, enzymes, and probiotics for the food and dairy industries); Health and Nutrition (develops products for the dietary supplement, over-the-counter pharmaceutical, infant formula, and animal feed industries); and Natural Colors (develops natural color solutions to the food industry, primarily for the beverage, dairy, confectionery, fruit preparation and ice cream, as well as functional blends for processed meats).
  • TickerCHR
  • ISINDK0060227585
  • ExchangeNasdaq Nordic Copenhagen
  • SectorPharmaceuticals & Biotechnology
  • CountryDenmark

Analysts

1 director bought

A director at Chr.Hansen Holding AS bought 775 shares at 642.950DKK and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names o...

Christer Magnergård ...
  • Christoffer Wang Bjørnsen
  • Joachim Gunell
  • Mattias Holmberg
  • Nicolas McBeath
  • Nicolay Dyvik
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Tomi Railo

Northern Lights

Rune Majlund Dahl

Chr. Hansen (Hold, TP: DKK670.00) -

Q2 2018/19 organic growth, reported revenue and EBIT missed our forecasts and consensus, with an unexpected beat from FC&E and disappointments from H&N and NC. The 2018/19 group organic revenue growth guidance of 9–11% was kept, but at a divisional level NC was cut to 5–7% (6–9%). We reiterate our DKK670 target price, but have upgraded the stock to HOLD (SELL) following today’s share price decline.

Ioannis Pontikis

Morningstar | Chr. Hansen Reports Second-Quarter Results, Announces Pharma Joint Venture With Lonza

From its origins as a cheese rennet producer, Chr. Hansen has transformed into a pioneer in offering microbial and natural color solutions for the food, beverage, and pharmaceutical markets. Our wide economic moat rating is supported by its intangible assets, switching costs, and a cost edge resulting from the company’s years of high R&D spending, strong client relationships, proprietary technology/client data, and leadership position in each of the three markets in which it operates.Growth is secular and driven mainly by health and wellness trends, including removing undesirable content from ...

Rune Majlund Dahl

Chr. Hansen (Hold, TP: DKK670.00) -

Q2 2018/19 organic growth, reported revenue and EBIT missed our forecasts and consensus, with an unexpected beat from FC&E and disappointments from H&N and NC. The 2018/19 group organic revenue growth guidance of 9–11% was kept, but at a divisional level NC was cut to 5–7% (6–9%). We reiterate our DKK670 target price, but have upgraded the stock to HOLD (SELL) following today’s share price decline.

Ioannis Pontikis

Morningstar | Chr. Hansen Reports Second-Quarter Results, Announces Pharma Joint Venture With Lonza

From its origins as a cheese rennet producer, Chr. Hansen has transformed into a pioneer in offering microbial and natural color solutions for the food, beverage, and pharmaceutical markets. Our wide economic moat rating is supported by its intangible assets, switching costs, and a cost edge resulting from the company’s years of high R&D spending, strong client relationships, proprietary technology/client data, and leadership position in each of the three markets in which it operates.Growth is secular and driven mainly by health and wellness trends, including removing undesirable content from ...

Ioannis Pontikis

Chr. Hansen Reports Second-Quarter Results, Announces Pharma Joint Venture With Lonza

Chr. Hansen reported second-quarter and semiannual results for fiscal 2019 with group sales growth of 8% (6% volume, 2% pricing) and 7% (6% volume, 3% pricing), respectively, broadly in line with our estimates. The company also announced the signing of an agreement with Lonza to create a strategic joint venture in the contract manufacturing market for bacteria-based pharmaceuticals (live biotherapeutics), which bonds well with the company's aspiration to further develop its human microbiome ligh...

Ioannis Pontikis

Morningstar | Chr. Hansen Reports 2Q Results, Announces Pharma Joint Venture With Lonza; Shares Rich

Chr. Hansen reported second-quarter and semiannual results for fiscal 2019 with group sales growth of 8% (6% volume, 2% pricing) and 7% (6% volume, 3% pricing), respectively, broadly in line with our estimates. The company also announced the signing of an agreement with Lonza to create a strategic joint venture in the contract manufacturing market for bacteria-based pharmaceuticals (live biotherapeutics), which bonds well with the company's aspiration to further develop its human microbiome lighthouse and utilize its unique microbial capabilities. Group EBIT margin before special items was up ...

Ioannis Pontikis

Chr. Hansen Reports 2Q Results, Announces Pharma Joint Venture With Lonza; Shares Rich

Chr. Hansen reported second-quarter and semiannual results for fiscal 2019 with group sales growth of 8% (6% volume, 2% pricing) and 7% (6% volume, 3% pricing), respectively, broadly in line with our estimates. The company also announced the signing of an agreement with Lonza to create a strategic joint venture in the contract manufacturing market for bacteria-based pharmaceuticals (live biotherapeutics), which bonds well with the company's aspiration to further develop its human microbiome ligh...

1 director bought

A director at Chr.Hansen Holding AS bought 775 shares at 642.950DKK and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names o...

Christer Magnergård ...
  • Christoffer Wang Bjørnsen
  • Joachim Gunell
  • Mattias Holmberg
  • Nicolas McBeath
  • Nicolay Dyvik
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Tomi Railo

Northern Lights

Eivind Sars Veddeng ...
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Alexander Aukner ...
  • Antti Kansanen
  • Jon Masdal
  • Marius Knudssøn
  • Martin Arnell
  • Martin Huseby Karlsen
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Frank Maaø ...
  • Håkon Astrup
  • Jesper Ingildsen
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Marius Knudssøn
  • Martin Arnell
  • Martin Huseby Karlsen
  • Mattias Holmberg
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Christer Roth ...
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Martin Huseby Karlsen
  • Mattias Holmberg
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

A double requalification allows CHR HANSEN HOLDING AS to improve to Slightly Positive

CHR HANSEN HOLDING AS (DK), a company active in the Food Products industry, has received a double requalification by the independent financial analyst theScreener. Its fundamental valuation is now 2 out of 4 stars while its market behaviour can be considered as defensive. theScreener believes that the gain of a star(s) and an improvement in the market risk perception allows upgrading the general evaluation to Slightly Positive. As of the analysis date January 11, 2019, the closing price was DKK 621.60 and its potential was estimated at DKK 682.85.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

CHR Hansen – Proxinvest Corporate Governance Rating ® : B

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Expert Corporate Governance Service (ECGS)

CHR Hansen Holding - 2018, November 29

In general, Chr. Hansen is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting. In April 2018, Chr. Hansen presented an updated corporate strategy for the period until 2022. The name is still Nature's no. 1, but now with the subtitle 'Sustainably'. The strategic pillars remain the same and the Company's financial ambitions were also updated. On an organisational level, Mr. Mauricio Graber has been appointed as the new CEO of Chr. Hansen as of June 1, 2018 and thereby succeeded Mr. Cees de Jong, who decided to pursue a career as ...

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 28/11/2017

In general, Chr. Hansen is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting.Under ITEM 5c, it is proposed to abolish the age limit for members of the board of directors in the Company's Articles of Association. Since this proposal is currently not in accordance with provision 3.1.4 of the Danish Recommendations on Corporate Governance, ECGS recommends to OPPOSE.Under ITEMS 6aa-6bf, the (re-)election of the board of directors is proposed. ECGS has concerns over the aggregate time commitments of board Chairman Mr. Ole Gjesso And...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch